Cargando…
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have been for non-cancer drugs and indications. This represents mu...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419407/ https://www.ncbi.nlm.nih.gov/pubmed/32557274 http://dx.doi.org/10.1007/s40268-020-00311-6 |